CIK: 0002043476
Total reported value
$134.9M
Reporting period: 2026-03-31 · Number of holdings: 20
B Group, Inc. disclosed 20 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $134.9M and a quarterly turnover rate of 43.3%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "B"
B Group, Inc.'s disclosed holdings carry a Herfindahl concentration index of 0.100 — mathematically equivalent to about 10 equally-sized positions, well below its 20 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 1.03), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 7.5 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 21% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim ADMA
+30.5% -$15.9M
Add PALI
+153.7% $9.4M
Trim CLLS
0.0% -$5.5M
Trim SGHT
+5.4% -$3.6M
Trim TSHA
0.0% -$1.9M
Add SYRE
0.0% $1.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics INC | Stock-Healthcare | 21.43% | -11.67% | +30.52% | |
| 2 | PALI | Palisade Bio INC | Stock-Other | 14.81% | +7.00% | +153.65% | |
| 3 | PRAX | Praxis Precision Medicines I | Stock-Other | 7.94% | +0.71% | — | |
| 4 | CLLS | Cellectis - Adr | Stock-Other | 7.71% | -4.02% | — | |
| 5 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 6.28% | +1.07% | +12.66% | |
| 6 | TSHA | Taysha Gene Therapies INC | Stock-Other | 5.97% | -1.34% | — | |
| 7 | NRXP | Nrx Pharmaceuticals INC | Stock-Other | 4.74% | +4.74% | NEW | |
| 8 | GPCR | Structure Therapeutics INC | Stock-Other | 4.56% | -0.06% | +41.67% | |
| 9 | IOVA | Iovance Biotherapeutics INC | Stock-Other | 3.90% | +0.88% | — | |
| 10 | SYRE | Spyre Therapeutics INC | Stock-Other | 3.74% | +1.32% | — | |
| 11 | DRUG | Bright Minds Biosciences INC | Stock-Other | 3.65% | +3.65% | NEW | |
| 12 | ASMB | Assembly Biosciences INC | Stock-Other | 3.61% | -0.80% | — | |
| 13 | AURA | Aura Biosciences INC | Stock-Other | 2.96% | +0.66% | +4.37% | |
| 14 | ORKA | Oruka Therapeutics INC | Stock-Other | 2.73% | +1.05% | — | |
| 15 | SGHT | Sight Sciences INC | Stock-Other | 2.71% | -2.68% | +5.43% | |
| 16 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.10% | -0.19% | — | |
| 17 | APGE | Apogee Therapeutics INC | Stock-Other | 0.47% | -0.64% | -62.50% | |
| 18 | FHTX | Foghorn Therapeutics INC | Stock-Other | 0.36% | +0.36% | NEW | |
| 19 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.19% | +0.19% | NEW | |
| 20 | REPL | Replimune Group INC | Stock-Other | 0.15% | -0.21% | -48.00% |
Performance for Q3 2026
-5.6%
Performance Last 4 Quarters
+12.5%
Based on 71% of reported portfolio value with available pricing
B Group, Inc.'s most significant position changes for 2026-03-31: New buy: Nrx Pharmaceuticals INC (NRXP); New buy: Bright Minds Biosciences INC (DRUG); New buy: Foghorn Therapeutics INC (FHTX); New buy: Soleno Therapeutics INC (SLNOEUR); Add: Adma Biologics INC (ADMA) — shares +30.52%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PALI | Palisade Bio INC | +7% | +153.65% | Add |
| 2 | SYRE | Spyre Therapeutics INC | +1.3% | — | Unchanged |
| 3 | ZLAB | Zai Lab Ltd-adr | +1.1% | +12.66% | Add |
| 4 | ORKA | Oruka Therapeutics INC | +1.1% | — | Unchanged |
| 5 | IOVA | Iovance Biotherapeutics INC | +0.9% | — | Unchanged |
| 6 | PRAX | Praxis Precision Medicines I | +0.7% | — | Unchanged |
| 7 | AURA | Aura Biosciences INC | +0.7% | +4.37% | Add |
| 8 | GPCR | Structure Therapeutics INC | -0.1% | +41.67% | Add |
| 9 | RARE | Ultragenyx Pharmaceutical In | -0.2% | — | Unchanged |
| 10 | REPL | Replimune Group INC | -0.2% | -48.00% | Trim |
| 11 | APGE | Apogee Therapeutics INC | -0.6% | -62.50% | Trim |
| 12 | ASMB | Assembly Biosciences INC | -0.8% | — | Unchanged |
| 13 | TSHA | Taysha Gene Therapies INC | -1.3% | — | Unchanged |
| 14 | SGHT | Sight Sciences INC | -2.7% | +5.43% | Add |
| 15 | CLLS | Cellectis - Adr | -4% | — | Unchanged |
| 16 | ADMA | Adma Biologics INC | -11.7% | +30.52% | Add |
| 17 | NRXP | Nrx Pharmaceuticals INC | — | NEW | New buy |
| 18 | DRUG | Bright Minds Biosciences INC | — | NEW | New buy |
| 19 | FHTX | Foghorn Therapeutics INC | — | NEW | New buy |
| 20 | SLNOEUR | Soleno Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001896071
Total reported value
$134.9M
1 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002134988
Total reported value
$134.9M
9 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001909572
Total reported value
$134.8M
86 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000938206
Total reported value
$13.6B
356 stks
2026-03-31
1 of the top 5 holdings overlap, including Praxis Precision Medicines I
CIK 0001009258
Total reported value
$8.5B
82 stks
2026-03-31
1 of the top 5 holdings overlap, including Praxis Precision Medicines I
CIK 0001224962
Total reported value
$5.1B
94 stks
2026-03-31
1 of the top 5 holdings overlap, including Praxis Precision Medicines I